Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue. METHODS: We conducted a multisite, double-blind, placebo-controlled study of the treatment of major depression characterized by excessive sleepiness and fatigue, adding adjunctive modafinil or placebo to a selective serotonin reuptake inhibitor from the beginning of treatment. Seventy-three of 90 consenting patients met all screening criteria to begin treatment with open-label selective serotonin reuptake inhibitor therapy and double-blind addition of either modafinil (100 mg/d for 1 week then 200 mg/d) or matching placebo for 6 weeks. RESULTS: Mixed-model analysis of the change in the Epworth Sleepiness Scale, the primary outcome measure, showed no difference between modafinil- and placebo-treated patients. However, the hypersomnia items on the 31-item Hamilton Depression Scale were significantly more improved with modafinil than placebo. The total 31-item Hamilton Depression Scale score was significantly better with modafinil than placebo at Weeks 4 and 5, but not at the final study visit. There was no difference in dropout rates caused by adverse events, but 2 patients in the modafinil-treated group developed new onset or worsening of suicidal ideation, leading to the trial being discontinued prematurely. CONCLUSIONS: Power to detect differences between modafinil and placebo was limited because of the premature discontinuation of the trial. Although modafinil did not show evidence of benefit over placebo on the Epworth Sleepiness Scale, secondary measures suggested modafinil may have provided benefit for symptoms of excessive sleepiness in patients with depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Although remission is the goal of antidepressant treatment,(2) rates of remission in clinical trials of antidepressants are usually around 35%,(3) even when treatment is extended to 14 weeks.(4) Among those who respond”
BackgroundAnderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480 · cited 1×
“Another recent, placebo-controlled, randomized trial (n = 545) demonstrated benefit in response and remission rates with the addition of eszopiclone to fluoxetine in subjects with depression with significant insomnia.(30) The lack of difference between the 2 treatment groups in the current study on overall depression…”
BackgroundResidual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470
Suicide Risk During Antidepressant Treatment
Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.41 · Cited by 424
Modafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea
PACK, A. I., BLACK, J. E., SCHWARTZ, J. R. L., & MATHESON, J. K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103032 · Cited by 324
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252
Is there a delay in the antidepressant effect? A meta-analysis
Posternak, M. A., & Zimmerman, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0201 · Cited by 250
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144 · cited 1×
“Case reports and controlled studies suggest that modafinil, a novel wakefulness-promoting agent, may provide benefit as an adjunctive therapy for patients with partial response or nonresponse to antidepressants.(11,12) A recent, large, placebo-controlled, double-blind, randomized trial of modafinil augmentation of SSR…”
BackgroundSelf-citationResidual symptoms in depression
Fava, G. A., Fabbri, S., & Sonino, N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00226-9 · Cited by 137
Cited by
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
“Moreover, negative studies for modafanil in MDD provide rationale for not recommending it as a broad-based treatment for TRD (though efficacy against fatigue and somnolence is suggested) (DeBattista et al., 2003; Dunlop et al., 2007; Fava et al., 2005).”
BackgroundApproved and Investigational Uses of Modafinil: An Evidence-Based Review
Kumar, R. (2008) · Drugs · doi:10.2165/00003495-200868130-00003 · Cited by 415
Pharmacological treatments for fatigue associated with palliative care
Mücke, M., Mochamat, M., Cuhls, H., Peuckmann-Post, V., Minton, O., Stone, P., & Radbruch, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006788.pub3 · Cited by 227
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
The vigilance regulation model of affective disorders and ADHD
Hegerl, U., & Hensch, T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.008 · Cited by 212
Metadata
- Authors
- Dunlop, B. W., Crits-Christoph, P., Evans, D. L., Hirschowitz, J., Solvason, H. B., Rickels, K., Garlow, S. J., Gallop, R. J., & Ninan, P. T.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-12
- Volume
- 27
- Issue
- 6
- Pages
- 614-619
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2043871213
- Cited by
- 56
- References
- 10
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e31815abefb
- The paper
- Dunlop, B. W., Crits-Christoph, P., Evans, D. L., Hirschowitz, J., Solvason, H. B., Rickels, K., Garlow, S. J., Gallop, R. J., & Ninan, P. T. (2007). Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31815abefb
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.